ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

30-09-2016

ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

Nyon, Switzerland and Potsdam, Germany, September 30, 2016 — Elanix Biotechnologies AG (“Elanix” – FSE: ELN), a developer of tissue regeneration products, announced today that Elanix-Technologies SA in Nyon, Switzerland (a 100% subsidiary of Elanix Biotechnologies AG, Potsdam) entered into a purchase agreement to acquire 100% of equity of Repair-A SA, a Lausanne based pharma and cosmetic company. It has been agreed not to disclose the sum involved.

Repair-A SA is owner of two medical cosmetic products to alleviate dermatological and gynecological conditions. Elanix already has an exclusivity to sell both products in CH and EU, with this acquisition Elanix will be able to fully control the product formulation, production and commercialization world-wide. Elanix anticipates significant sales growth in the coming months through combination of direct and distributor sales in Switzerland, Europe and beyond.

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanixbiotechnologies.com.

Press Contact:

Elanix Biotechnologies AG investor.relations@elanix.ch

Disclaimer / Forward-looking statements:

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.